PROASSURANCE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.52 USD | -1.65% |
|
-0.71% | -9.21% |
| Sales 2024 * | 111.36Cr 9.31TCr | Sales 2025 * | 112.99Cr 9.44TCr | Capitalization | 64Cr 5.34TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 2Cr 167.12Cr | Net income 2025 * | 3.3Cr 275.76Cr | EV / Sales 2024 * | 0.57 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.57 x |
| P/E ratio 2024 * |
31.7
x | P/E ratio 2025 * |
18.9
x | Employees | 1,094 |
| Yield 2024 * |
1.28% | Yield 2025 * |
1.28% | Free-Float | 79.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProAssurance Corporation
More recommendations
More press releases
| 1 day | -1.65% | ||
| 1 week | -0.71% | ||
| Current month | -12.87% | ||
| 1 month | -14.66% | ||
| 3 months | +2.79% | ||
| 6 months | -11.71% | ||
| Current year | -9.21% |
1 week
12.33
12.86
1 month
12.1714.78
Current year
11.7615.90
1 year
11.7619.38
3 years
11.7627.55
5 years
11.7642.03
10 years
11.7663.53
| Managers | Title | Age | Since |
|---|---|---|---|
Edward Rand
CEO | Chief Executive Officer | 57 | 01/04/01 |
Dana Hendricks
DFI | Director of Finance/CFO | 56 | 01/18/01 |
| Chief Investment Officer | - | 24/14/24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Edward Rand
CEO | Chief Executive Officer | 57 | 01/04/01 |
Bruce Angiolillo
CHM | Chairman | 71 | 01/16/01 |
Samuel di Piazza
BRD | Director/Board Member | 73 | 21/14/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 28 M€ | -4.78% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/24/25 | 12.52 | -1.65% | 258,627 |
| 24/24/24 | 12.73 | +1.60% | 266,642 |
| 21/24/21 | 12.53 | -2.19% | 998,298 |
| 20/24/20 | 12.81 | +1.59% | 263,139 |
| 18/24/18 | 12.61 | +0.56% | 411,726 |
Delayed Quote Nyse, June 26, 2024 at 01:30 am IST
More quotes
ProAssurance Corporation is a specialty insurer with expertise in healthcare professional liability, products liability for medical technology and life sciences, legal professional liability, and workers' compensation insurance. The Company's segments include Specialty P&C, Workers' Compensation Insurance, Segregated Portfolio Cell Reinsurance and Corporate. The Specialty Property and Casualty (Specialty P&C) segment is focused on professional liability insurance and medical technology liability insurance. Professional liability insurance is offered to healthcare providers and institutions and, to a lesser extent, to attorneys and their firms. The Workers' Compensation Insurance segment offers workers' compensation products in approximately 19 states in the East, South and Midwest regions of the continental United States. The Segregated Portfolio Cell Reinsurance segment includes the results of SPCs at Inova Re and Eastern Re, the Company's Cayman Islands SPC operations.
Calendar
06/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
12.52
USD
Average target price
17.5
USD
Spread / Average Target
+39.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.21% | 64Cr | |
| +64.78% | 7.1TCr | |
| +9.98% | 4.94TCr | |
| +9.57% | 4.78TCr | |
| +15.26% | 4.26TCr | |
| +37.54% | 3.82TCr | |
| +83.81% | 3.34TCr | |
| +11.31% | 2.96TCr | |
| +24.94% | 2.53TCr | |
| +1.16% | 2.16TCr |
- Stock Market
- Equities
- PRA Stock
